LitCovid-sentences  

PMC:7417114 / 68693-70618 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T535 0-15 Sentence denotes EGFR inhibitors
T536 16-192 Sentence denotes Studies suggest that inhibiting EGFR signaling might prevent an excessive fibrotic response to SARS-CoV and other respiratory infections (like that characteristic of COVID-19).
T537 193-349 Sentence denotes EGFR plays a role in interstitial lung disease, and interaction between EGF and TFG-beta signaling is believed to drive development of fibrosis (116) (117).
T538 350-582 Sentence denotes The role of EGFR signaling in the development of lung fibrosis is complex, though, with data suggesting both profibrotic and antifibrotic roles for EGFR signaling, at least in part seeming to depend on the trigger for fibrosis (13).
T539 583-807 Sentence denotes Gefitinib inhibited TGF-beta1 induction of fibrosis in vivo (118) and inhibited bleomycin-induced fibrosis in a mouse model (119), and erlotinib was reported to block fibrosis development in a variety of in vivo models (13).
T540 808-885 Sentence denotes TGF-beta induces the expression of EGFR ligands, which in turn activate EGFR.
T541 886-1169 Sentence denotes Of relevance, TGF-beta was one of several pro-inflammatory cytokines that were observed to be highly upregulated in SARS-CoV patients (120) (121) (122), and mouse models of SARS-CoV infection showed interferon, cytokine and lung-associated wound-healing and ARDS-related genes (123).
T542 1170-1281 Sentence denotes These findings are consistent with TGF-beta being profibrotic, as has been demonstrated in animal models (124).
T543 1282-1550 Sentence denotes The kinase inhibitor, sorafenib, attenuated bleomycin-induced pulmonary fibrosis in a preclinical model (125) and ameliorated fibrosis in liver fibrosis models through STAT3 inhibition and downregulation of TGF-beta- and PDGFRβ-mediated pathways of fibrogenesis (126).
T544 1551-1766 Sentence denotes The EGFR inhibitor, osimertinib, is metabolized and broken down into two pharmacologically active metabolites (AZ7550 and AZ5104), which circulate at around 10% of the concentration of the parent compound (Table 3).
T545 1767-1925 Sentence denotes One metabolite, AZ5104, which is more potent than osimertinib, downregulates Th17-related cytokine production via inhibition of SRC-ERK-STAT3 (127) (Table 2).